NVLN - Novelion Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.93
+0.07 (+8.75%)
As of 3:42PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.86
Open0.96
Bid0.91 x 1100
Ask0.93 x 3000
Day's Range0.87 - 0.96
52 Week Range0.70 - 5.87
Volume425,852
Avg. Volume1,809,260
Market Cap17.607M
Beta (3Y Monthly)3.79
PE Ratio (TTM)N/A
EPS (TTM)-6.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2013-06-28
1y Target Est6.50
Trade prices are not sourced from all markets
  • ACCESSWIRE6 hours ago

    New Healthcare Trends Could Push Sector Stocks Higher

    CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.

  • Benzinga8 hours ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • GlobeNewswireyesterday

    Novelion Therapeutics Announces Leadership Change

    Novelion Therapeutics Inc. (NVLN), today announced that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately. Jeffrey Hackman resigned as interim CEO to pursue another opportunity and will stay with the Company in a transitional role until November 30, 2018. Dr. Corrigan commented, “In the past year, we have made substantial progress in the turnaround of Novelion, and on behalf of the Board of Directors, I’d like to thank Jeff for his dedication to this mission.

  • GlobeNewswire12 days ago

    Novelion Therapeutics Reports Third Quarter 2018 Financial Results

    VANCOUVER, British Columbia, Nov. 09, 2018 -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for.

  • ACCESSWIRE12 days ago

    Today’s Research Reports on Stocks to Watch: Perrigo Company and Novelion Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 9, 2018 / While shares of healthcare company Perrigo Company were tanking after reporting third quarter financial results, Novelion Therapeutics, which is developing ...

  • GlobeNewswire13 days ago

    Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”), after soliciting third party lenders, has entered into a new secured financing facility with certain funds managed by Athyrium Capital Management (Athyrium) and Highbridge Capital Management, LLC (Highbridge) (the “New Lenders”). The facility consists of $50.0 million in new secured first lien term loans that were funded to Aegerion in cash and $22.5 million of new secured term loans that were used, on behalf of Aegerion, to retire an equal amount of Aegerion’s 2% convertible notes due August 2019, at par, held by certain funds managed by each of Athyrium and Highbridge.

  • GlobeNewswire2 months ago

    Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH Foundation’s annual Familial Hypercholesterolemia (FH) Awareness Day. Interim Chief Executive Officer Jeff Hackman said, "We share The FH Foundation’s mission of increasing awareness of FH, including homozygous FH (HoFH), a very serious and often undiagnosed disease.

  • Associated Press3 months ago

    Novelion Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.67. Losses, adjusted for amortization costs and non-recurring costs, came to 59 cents per share. The retinal ...

  • GlobeNewswire5 months ago

    Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

    Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic ...

  • Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)?
    Simply Wall St.5 months ago

    Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)?

    Novelion Therapeutics Inc (NASDAQ:NVLN), a US$76.13M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • GlobeNewswire6 months ago

    MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

    Novelion Therapeutics Inc. (NVLN.TO), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorization, under exceptional circumstances, for MYALEPTA.

  • Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)
    Simply Wall St.6 months ago

    Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)

    Novelion Therapeutics Inc’s (NASDAQ:NVLN): Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. With theRead More...

  • Reuters6 months ago

    Former Aegerion sales rep charged with defrauding U.S. insurers

    A former Aegerion Pharmaceuticals Inc sales representative was arrested Tuesday on charges that he defrauded insurance companies into paying for the company's expensive cholesterol drug. Mark Moffett was charged with wire fraud and conspiracy in a criminal complaint unsealed in Massachusetts federal court. "Mark is an innocent man," Kenneth Cunniff, Moffett's lawyer, said in an email.

  • Associated Press6 months ago

    Novelion Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.76. Losses, adjusted for non-recurring costs and stock option expense, came to 72 cents per share. The retinal ...

  • Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?
    Simply Wall St.7 months ago

    Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?

    In December 2017, Novelion Therapeutics Inc (NASDAQ:NVLN) announced its most recent earnings update, which suggested that losses became smaller relative to the prrior year’s level – great news for investorsRead More...

  • Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.8 months ago

    Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?

    Measuring Novelion Therapeutics Inc’s (NASDAQ:NVLN) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • GlobeNewswire8 months ago

    Novelion Therapeutics Supports World Lipodystrophy Day

    VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living ...